Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Completed · Phase 4 · Has a placebo group
Conditions studied: Covid19, Sequelae of; Infection, Cognitive Symptom
In brief
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers"). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.
Key facts
- Study ID
- NCT04809974
- Run by
- Massachusetts General Hospital
- People needed
- 72
- Starts
- 2021-08-28
- Expected to finish
- 2024-02-23
- Last updated by the study team
- 2025-08-05
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- History of SARS-CoV-2 PCR+ at least 2 months prior to study entry;
- SARS-CoV-2 negative (PCR) at study entry;
- Persistent cognitive difficulties (esp. "brain fog") that began around the time of the acute COVID-19;
- At least two neurological and/or physical symptoms that started with COVID-19 infection and are ongoing at study entry, including fatigue, weakness, headache, loss of smell, tingling/numbness, shortness of breath, loss of appetite, palpitations/tachycardia, hair loss, musculoskeletal and/or chest pain;
- Willing and able to consent, complete all assessment and study procedures;
- Not pregnant or lactating.
You may not qualify if…
- Any specific central nervous system disease history (e.g. major clinical stroke, brain tumor, normal pressure hydrocephalus, etc);
- Clinically significant unstable medical condition that could affect safety or compliance with the study;
- Was intubated due to COVID-19;
- Major active or chronic unstable psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year;
- History of alcohol or other substance abuse or dependence within the past two years;
- Any significant systemic illness or medical condition that could affect safety or compliance with study;
- Current use of medications with psychoactive properties that may be deleteriously affecting cognition;
- Any known hypersensitivity to nicotinamide riboside, or its principal metabolite, nicotinamide mononucleotide;
- Use of other investigational agents or interventions one month prior to entry and for the duration of the trial;
- If participating in the optional magnetic resonance imaging (MRI) sub-study: Any contraindication to undergo MRI;
- Pregnant women or women who are planning to become pregnant within 7 months from study entry.
Where it is running
- Clinical Translational Research Unit — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.